 One patient with "ETV6-FLT3"-related myeloid/lymphoid neoplasm obtained a short term remission on sunitinib and following relapse, on sorafenib suggesting that the cited FLT3 protein tyrosine kinase inhibitors may prove useful for treating "ETV6-FLT"-related hematologic malignancies.Two patients suffering hematologic malignancies related to "PCM1-JAK2" or "BCR-JAK2" fusion genes experienced complete and cytogenetic remissions in response to the tyrosine kinase inhibitor ruxolitinib; while both remissions were short-term (12 months), these results suggest that tyrosine kinase inhibitors that target JAK2 may be of some use for treating hematologic malignancies associated with "ETV6-JAK2" fusion stems.An inhibitor of SYK tyrosine kinase, TAK-659 is currently undergoing Phase I clinical trials for advanced lymphoma malignancies and may prove to be useful in treating this disease when associated with the "ETV6-SYK" fusion gene.